Molbio Diagnostics IPO GMP Today, Price & Details
Molbio Diagnostics IPO GMP Today, Price Band, Subscription Status, Allotment & Listing Details
About Molbio Diagnostics
Molbio Diagnostics is set to launch its Mainboard IPO on the NSE, aiming to raise capital through a significant issue size of ₹940 Cr. The company operates in the diagnostics sector, a field that has seen robust growth and increasing importance, especially in recent times. This IPO comprises a fresh issue of ₹200 Cr and an Offer for Sale (OFS) component of ₹739.7 Cr, indicating that existing shareholders are looking to divest a portion of their stakes while the company also seeks funds for its expansion. The price band for the IPO has been set between ₹768 and ₹807 per share, with a lot size of 18 shares.
Financially, Molbio Diagnostics has demonstrated a strong performance. For the period ending March 2023, the company reported revenues of ₹1020.42 Cr and a Profit After Tax (PAT) of ₹138.58 Cr. This translates to an Earnings Per Share (EPS) of ₹8211, reflecting a healthy profitability. The company also boasts impressive return ratios, with a Return on Net Worth (RONW) of 15.23% and a Return on Capital Employed (ROCE) of 20.98%. The EBITDA margin stands at a solid 24.97%, underscoring efficient operational management. The Net Asset Value (NAV) per share is ₹84.51.
Molbio Diagnostics' competitive positioning seems to be bolstered by its financial metrics and operational efficiency, as suggested by its healthy margins and return ratios. The fresh issue proceeds of ₹200 Cr are earmarked for specific strategic purposes, which will be crucial for its future growth trajectory. The IPO is being managed by prominent lead managers, including Kotak Mahindra Capital Co.Ltd., IIFL Capital Services Ltd., Jefferies India Pvt.Ltd., and Motilal Oswal Investment Advisors Ltd., with Kfin Technologies Ltd. as the registrar. This collective effort aims to bring the company to the public markets successfully.
Molbio Diagnostics IPO — Investment Analysis
Molbio Diagnostics' IPO is priced within a band of ₹768 to ₹807 per share. With an EPS of ₹8211, the company's P/E ratio at the upper end of the price band stands at approximately 56.67x. This valuation needs to be considered in the context of the diagnostics sector's growth potential and the company's financial performance. While the P/E is on the higher side, it's essential to compare it with industry peers and consider the company's profitability and future prospects. The substantial EPS suggests strong earnings generation relative to its face value, but investors should also look at the absolute earnings and growth trajectory.
From a financial health perspective, Molbio Diagnostics presents a compelling picture. The company has achieved revenues of ₹1020.42 Cr and a PAT of ₹138.58 Cr, indicating strong top-line growth and bottom-line profitability. The EBITDA margin of 24.97% is particularly noteworthy, signifying efficient cost management and operational leverage. Furthermore, return ratios like RONW at 15.23% and ROCE at 20.98% suggest that the company is effectively utilizing its capital to generate profits. These metrics point towards a well-managed and financially sound business.
The growth outlook for Molbio Diagnostics appears positive, given the expanding healthcare sector in India. However, potential investors should be mindful of the IPO structure. The significant OFS component of ₹739.7 Cr means a substantial portion of the IPO proceeds will go to selling shareholders rather than the company itself, which might temper the immediate impact of the IPO on corporate expansion. Sector-specific risks, such as regulatory changes or increased competition, are always present. Additionally, any concerns related to Small and Medium-sized Enterprises (SME) in the company's supply chain or customer base could pose indirect risks.
Investor sentiment for an IPO is often gauged by subscription levels across different investor categories. High subscription from Qualified Institutional Buyers (QIBs) and High Net-worth Individuals (HNIs) can indicate institutional confidence in the company's long-term prospects. Robust retail subscription, on the other hand, shows broader public interest. Analyzing these subscription trends can provide insights into market perception, but it's crucial to remember that past performance and current sentiment are not guarantees of future returns. Investors should consult a SEBI-registered financial advisor before making investment decisions.
Disclaimer: This analysis is auto-generated from publicly available financial data and should not be considered investment advice. Always consult a SEBI-registered financial advisor before making investment decisions.
Molbio Diagnostics IPO — Pros & Cons
Strengths
- The company has demonstrated strong financial performance with revenues reaching ₹1020.42 Cr and a PAT of ₹138.58 Cr. This robust financial track record suggests a well-established and profitable business model that can generate consistent returns for investors.
- Molbio Diagnostics exhibits impressive return ratios, with a RONW of 15.23% and a ROCE of 20.98%. These figures indicate efficient utilization of shareholder funds and capital employed, signaling a company that is adept at generating profits from its assets.
- The company's operational efficiency is highlighted by a healthy EBITDA margin of 24.97%. This strong margin suggests effective cost management and pricing power, which are crucial for sustained profitability and competitive advantage in the diagnostics sector.
- The IPO features a substantial fresh issue component of ₹200 Cr. These funds are intended for growth initiatives, which could lead to future expansion and increased shareholder value, provided the capital is deployed effectively.
- The diagnostics sector in India is poised for significant growth, driven by increasing healthcare awareness and expenditure. Molbio Diagnostics is well-positioned to capitalize on these industry tailwinds, potentially leading to sustained revenue and profit expansion.
Risks
- The P/E ratio at the upper price band of 56.67x appears relatively high. Investors need to assess if this valuation is justified by the company's growth prospects and compare it with industry benchmarks to avoid overpaying.
- The IPO includes a large OFS component of ₹739.7 Cr. This means a significant portion of the funds raised will go to existing shareholders, potentially limiting the immediate capital available for the company's growth and expansion plans.
- The Net Asset Value (NAV) per share stands at ₹84.51, while the IPO price band starts from ₹768. This implies investors are paying a substantial premium over the book value, which requires strong future earnings growth to justify.
- While the company operates in a growing sector, the diagnostics industry is becoming increasingly competitive. New entrants and established players could exert pricing pressure, impacting profit margins and market share.
- The limited financial data provided (only for the period ending March 2023) makes it challenging to assess the long-term financial trends and consistency of performance. A more extended financial history would offer a clearer picture of the company's operational trajectory.
Molbio Diagnostics IPO Details
| Company Name | Molbio Diagnostics |
|---|---|
| IPO Type | MAINBOARD |
| Exchange | NSE |
| Price Band | ₹768 - ₹807 |
| Face Value | ₹1 per share |
| Lot Size | 18 shares |
| Min Investment | ₹14,526 |
| Total Issue Size | ₹940.00 Cr |
|---|---|
| Fresh Issue | ₹200.00 Cr |
| Offer for Sale | ₹739.70 Cr |
| Registrar | Kfin Technologies Ltd. |
| Lead Manager | Kotak Mahindra Capital Co.Ltd., IIFL Capital Services Ltd., Jefferies India Pvt.Ltd., Motilal Oswal Investment Advisors Ltd. |
| IPO Status | Listed |
Molbio Diagnostics IPO Dates
Molbio Diagnostics IPO Subscription Status
Molbio Diagnostics IPO Listing Performance
Molbio Diagnostics IPO listed on NSE on 17 Aug 2026 at ₹980, a premium of 21.4% over the issue price of ₹807. Investors who received allotment made a profit of ₹3,114 per lot (18 shares) on listing day.
Molbio Diagnostics IPO — Key Highlights
- Molbio Diagnostics reported impressive revenues of ₹1020.42 Cr for the year ended March 2023, showcasing significant market presence.
- The company achieved a healthy PAT of ₹138.58 Cr, indicating strong profitability from its operations.
- With an EBITDA margin of 24.97%, Molbio Diagnostics demonstrates robust operational efficiency and cost control.
- The ROCE stands at a strong 20.98%, highlighting the company's effectiveness in generating returns on its capital employed.
- The IPO comprises a fresh issue of ₹200 Cr, which will be utilized for the company's growth and expansion initiatives.
- The price band for the IPO is set between ₹768 and ₹807 per share.
Molbio Diagnostics Financial Performance
| Metric (₹ Cr) | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Revenue | 332.46 | 836.56 | 1,020.42 |
| Expenses | 327.87 | 657.83 | 820.40 |
| Net Income (PAT) | 3.45 | 83.54 | 138.58 |
| Margin (%) | 1.04% | 9.99% | 0.18% |
Molbio Diagnostics IPO Valuations & Key Metrics
Valuation Ratios
| EPS | ₹8,211.00 |
|---|---|
| P/E Ratio | 56.67x |
| NAV | ₹84.51 |
| Debt/Equity | 8,211.000 |
Return Metrics
| RONW (%) | 15.23% |
|---|---|
| ROCE (%) | 20.98% |
| EBITDA Margin | 24.97% |
Molbio Diagnostics IPO Reservation / Allocation
Molbio Diagnostics IPO Lead Manager & Registrar
Book Running Lead Manager
Kotak Mahindra Capital Co.Ltd., IIFL Capital Services Ltd., Jefferies India Pvt.Ltd., Motilal Oswal Investment Advisors Ltd.
IPO Registrar
Kfin Technologies Ltd.
Molbio Diagnostics IPO — Frequently Asked Questions
What is Molbio Diagnostics IPO GMP today?
As of today, the Grey Market Premium (GMP) for Molbio Diagnostics IPO is ₹150 per share, indicating a potential listing premium of 18.6% above the issue price of ₹807.
What is the price band and lot size of Molbio Diagnostics IPO?
Molbio Diagnostics IPO has a price band of ₹768 to ₹807 per equity share with a face value of ₹1. The minimum lot size is 18 shares, requiring a minimum investment of ₹14,526 at the upper band.
What are the important dates for Molbio Diagnostics IPO?
Molbio Diagnostics IPO opens for subscription on 10 Aug 2026 and closes on 12 Aug 2026. Allotment is expected on 13 Aug 2026. The shares are expected to list on NSE on 17 Aug 2026.
What is the investor category allocation in Molbio Diagnostics IPO?
The shares are reserved as follows — Qualified Institutional Buyers (QIB): 0.00%, Non-Institutional Investors (NII/HNI): 0.00%, and Retail Individual Investors: 35.00%.
How can I apply for Molbio Diagnostics IPO?
You can apply for Molbio Diagnostics IPO through your bank's net banking ASBA facility or via UPI-based application through any stockbroker platform. Ensure you have sufficient funds in your bank account as the amount will be blocked until allotment. The registrar for this IPO is Kfin Technologies Ltd..
What is the subscription status of Molbio Diagnostics IPO?
Molbio Diagnostics IPO has been subscribed 186.39 times overall. Retail category: 12.97x, NII/HNI: 49.80x, QIB: 186.39x.
What is Molbio Diagnostics IPO price band and lot size?
The Molbio Diagnostics IPO offers shares in a price band of ₹768 to ₹807 per equity share. Each lot consists of 18 shares. This means the minimum investment for a retail investor would be ₹14,526 (18 shares x ₹807).
The face value of each share is ₹1.
Is Molbio Diagnostics IPO worth investing in?
Molbio Diagnostics presents a mixed investment proposition. On the positive side, it boasts strong financial metrics like an EBITDA margin of 24.97% and a ROCE of 20.98%. However, the P/E ratio of around 56.67x at the upper band is on the higher side, and the substantial OFS component of ₹739.7 Cr means not all funds directly fuel company growth.
This IPO might be suitable for investors comfortable with growth valuations and who believe in the long-term potential of the Indian diagnostics sector. It's crucial to weigh the company's performance against its valuation and consider the risks involved. Investors should consult a SEBI-registered financial advisor before making investment decisions.
What is Molbio Diagnostics IPO GMP today?
Grey Market Premium (GMP) for the Molbio Diagnostics IPO is an unofficial indicator of market sentiment and potential listing gains. While specific GMP figures fluctuate, it's important to remember that GMP is not regulated and should not be the sole basis for investment decisions. It's advisable to check reliable financial news sources for the latest GMP trends, but always prioritize the company's fundamentals and your investment objectives.
How to apply for Molbio Diagnostics IPO?
You can apply for the Molbio Diagnostics IPO through either the ASBA (Application Supported by Blocked Amount) facility via your bank or through the UPI (Unified Payments Interface) mechanism. Most brokers facilitate applications through their platforms, which link to your demat account. Ensure you have sufficient funds or credit limit available for the ASBA application or that your UPI mandate is ready.
Your funds will remain blocked until the allotment process is completed.